Tuberculosis vaccination versus isoniazid preventive therapy: A decision analysis to determine the preferred strategy of tuberculosis prevention in HIV-infected adults in the developing world

International Journal of Tuberculosis and Lung Disease

Volumn 3, Issue 3, 1999, Pages 248-254

  Sterling, T R ^a,b,c   Brehm, W T ^a   Moore, R D ^b   Chaisson, R E ^b  

^a KEESLER MEDICAL CENTER   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Division of Infectious Diseases   (United States)

Author keywords

BCG vaccine; Decision analysis; HIV 1; Isoniazid preventive therapy; Tuberculosis

Indexed keywords

BCG VACCINE; ISONIAZID;

ARTICLE; DECISION MAKING; DRUG EFFICACY; DRUG SAFETY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN TISSUE; INFECTION PREVENTION; MAJOR CLINICAL STUDY; PREVALENCE; PRIORITY JOURNAL; TREATMENT PLANNING; TUBERCULOSIS; TUBERCULOSIS CONTROL;

ADULT; ANTITUBERCULAR AGENTS; BCG VACCINE; DECISION SUPPORT TECHNIQUES; DEVELOPING COUNTRIES; HIV INFECTIONS; HUMANS; IMMUNOCOMPROMISED HOST; ISONIAZID; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME; TUBERCULIN TEST; TUBERCULOSIS;

EID: 0033003149     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (44)

1. Selwyn P A, Hartel D, Lewis V A, et al. A prospective study of the risk of tuberculosis among intravenous drug users with human immunodeficiency virus infection. N Engl J Med 1989; 320: 1545-1550.
2. Pape J W, Jean S S, Ho J L, Hafner A, Johnson W D Jr. Effect of isoniazid prophylaxis on incidence of active tuberculosis and progression of HIV infection. Lancet 1993; 342: 268-272.
3. Whalen C C, Johnson J L, Okwera A, et al. A trial of three regimens to prevent tuberculosis in Ugandan adults infected with the human immunodeficiency virus. N Engl J Med 1997; 337: 801-808.
4. Moreno S, Baraia-Extaburu J, Bouza L, et al. Risk for developing tuberculosis among anergic patients infected with HIV. Ann Intern Med 1993; 119: 194-198.
5. Gonzalez del Riego M P, Bishai W R, Graham N M H, et al. The molecular epidemiology of tuberculosis in Haiti. Am J Respir Crit Care Med 1997; 155(Vol 4 part 2): A226.
6. Small P M, Hopewell P G, Singh S P, et al. The epidemiology of tuberculosis in San Francisco - a population-based study using conventional and molecular methods. N Engl J Med 1994; 330: 1703-1709.
7. Alland D, Kalkut G E, Moss A R, et al. Transmission of tuberculosis in New York City - an analysis by DNA fingerprinting and conventional epidemiologic methods. N Engl J Med 1994; 330: 1710-1716.
8. Pablos-Mendez A, Raviglione M C, Laszlo A, et al. Global surveillance for antituberculosis-drug resistance, 1994-1997. N Engl J Med 1998; 338: 1641-1649.
9. WHO. Tuberculosis preventive therapy in HIV-infected individuals. Wkly Epidemiol Rec 1993; 68: 361-368.
10. Colditz G A, Brewer T F, Berkey C S, et al. Efficacy of BCG vaccine in the prevention of tuberculosis: meta-analysis of the published literature. JAMA 1994; 271: 698-703.
11. Comstock G W. Field trials of tuberculosis vaccines: How could we have done them better? Controlled Clin Trials 1994; 15: 247-276.
12. Fine P E M. Randomised controlled trial of single BCG, repeated BCG, or combined BCG and killed Mycobacterium leprae vaccine for prevention of leprosy and tuberculosis in Malawi. Lancet 1996; 348: 17-24.
13. Marsh B J, von Reyn C F, Edwards J, et al. The risks and benefits of childhood BCG immunization among adults with AIDS. AIDS 1997; 11: 669-672.
14. Colebunders R L, Izaley L, Musampu M, Pauwels P, Francis H, Ryder R. BCG vaccine abscesses arc unrelated to HIV infection. JAMA 1988; 259: 352.
15. O'Brien K L, Ruff A J, Louis M A, et al. Bacillus Calmette Guerin complications in children born to HIV-1-infected women with a review of the literature. Pediatrics 1995; 95: 414-418.
16. Ryder R W, Oxtoby M J, Mvula M, et al. Safety and immunogenicity of bacille Calmette-Guerin, diphtheria-tetanus-pertussis, and oral polio vaccines in newborn children in Zaire infected with human immunodeficiency virus type 1. J Pediatr 1993; 122: 697-702.
17. Lallemant-Le Coeur S, Fallemant M, Cheynier D, Nzingoula S, Drucker J, Larouze B. Bacillus Calmette-Guerin immunization in infants born to HIV-1-seropositive mothers. AIDS 1991; 5: 195-199.
18. BCG vaccination and pediatric HIV infection - Rwanda, 1988-90. MMWR 1991; 40: 833-836.
19. The role of BCG vaccine in the prevention and control of tuberculosis in the United States. A joint statement by the Advisory Council for the Elimination of Tuberculosis and the Advisory Committee on Immunization Practices. MMWR 1996; 45(RR-4): 1-18.
20. Greenberg P D, Lax K G, Schechter C B. Tuberculosis in house staff. A decision analysis comparing the tuberculin screening strategy with the BCG vaccination. Am Rev Respir Dis 1991; 143: 490-495.
21. Weinstein M C, Fineberg H V. Clinical decision analysis. Philadelphia: WE Saunders, 1980.
22. Sonnenberg F A, Pauker S G. Decision Maker Version 7.0. Boston, MA. New England Medical Center; 1993.
23. Johnson M P, Coberly J S, Clermont H C, et al. Tuberculin skin test reactivity among adults infected with human immunodeficiency virus. J Infect Dis 1992; 166: 194-198.
24. Antonucci G, Girardi E, Raviglione M C, Ippolito G. Risk factors for tuberculosis in HIV-infected persons. JAMA 1995; 274: 143-148.
25. Markowitz N, Hansen N I, Wilcosky T C, et al. Tuberculin and anergy testing in HIV-seropositive and HIV-seronegative persons. Ann Intern Med 1993; 119: 185-193.
26. Graham N M H, Nelson K E, Solomon L, et al. Prevalence of tuberculin positivity and skin test anergy in HIV-1-seropositive and -seronegative intravenous drug users. JAMA 1992; 267: 369-373.
27. Selwyn P A, Sckell B M, Alcabes P, Friedland G H, Klein R S, Schoenbaum E E. High risk of active tuberculosis in HIV-infected drug users with cutaneous anergy. JAMA 1992; 268: 504-509.
28. Graham N M H, Galai N, Nelson K H, et al. Effect of isoniazid chemoprophylaxis on HIV-related mycobacterial disease. Arch Intern Med 1996; 156: 889-894.
29. Raviglione M C, Snider D E Jr, Kochi A. Global epidemiology of tuberculosis - morbidity and mortality of a worldwide epidemic. JAMA 1995; 273: 220-226.
30. Guclar A, Gatell J M, Verdejo J, et al. A prospective study of the risk of tuberculosis among HIV-infected patients. AIDS 1993; 7: 1345-1349.
31. Salpeter S. Fatal INH-induced hepatitis. Its risk during chemoprophylaxis. West J Med 1993; 159: 560-564.
32. Kopanoff D E, Snider D E Jr, Caras G J. Isoniazid-related hepatitis: a US Public Health Service Cooperative Surveillance Study. Am Rev Respir Dis 1978; 117: 991-1001.
33. Dash L A, Comstock G W, Flynn J P G. Isoniazid preventive therapy. Am Rev Respir Dis 1980; 121: 1039-1044.
34. Byrd R B, Horn B R, Solomon D A, Griggs G A. Toxic effects of isoniazid in tuberculosis chemoprophylaxis. JAMA 1979; 241: 1239-1241.
35. Lotte A, Wasz-Hockert O, Poisson N. Second IUATLD study on complications induced by intradermal BCG-vaccination. Bull Int Union Tuberc Lung Dis 1988; 63: 47-59.
36. Small P M, Schecter G F, Goodman P C, Sande M A, Chaisson R E, Hopewell P C. Treatment of tuberculosis in patients with advanced human immunodeficiency virus infection. N Engl J Med 1991; 324: 289-294.
37. Perriens J H, St. Louis M E, Mukadi Y B, et al. Pulmonary tuberculosis in HIV-infected patients in Zaire. New Engl J Med 1995; 332: 779-784.
38. Chaisson R E, Shechter G F, Theuer C P, Rutherford G W, Echengerg D E, Hopewell P C. Tuberculosis in patients with the acquired immunodeficiency syndrome. Am Rev Respir Dis 1987; 136: 570-574.
39. Pablos-Mendez A, Sterling T R, Frieden T R. The relationship between delayed or incomplete treatment and all-cause mortality in patients with tuberculosis. JAMA 1996; 276: 1223-1228.
40. DeCock K M, Grant A, Porter J D H. Preventive therapy tor tuberculosis in HIV-infected persons: international recommendations, research, and practice. Lancet 1995; 345: 833-836.
41. WHO. BCG immunization and paediatric HIV infection. Wkly Epidemiol Rec 1992; 67: 129-132.
42. Ellner J J. The immune response in human tuberculosis - implications for tuberculosis control. J Infect Dis 1997; 176: 1351-1359.
43. Gordin F, Chaisson R E, Matts J, et al. A randomized trial of 2 months of rifampin and pyrazinamide versus 12 months of isoniazid for the prevention of tuberculosis in HIV-positive PPD-positive patients. Abstracts of the 5th Conference on Retroviruses and Opportunistic Infections, p. 223. 1998.
44. Halsey N A, Coberly J S, Desormeaux J, et al. Randomised trial of isoniazid versus rifampicin and pyrazinamide for prevention of tuberculosis in HIV-1 infection. Lancet 1998; 351: 786-792.